Samsung Bioepis reimagines and redefines the way medicines are made.
Samsung Bioepis is a biopharmaceutical company dedicated to unlocking the potential of biosimilar medicines and transforming the way
biologic therapies are brought to patients. Our mission is reflected in our name, bio-epis; literally meaning life (“bio”) and science (“episteme”) in Greek.
We want to enhance the lives of patients through our pioneering and innovative use of science and technology.
We are a young company, challenging traditional approaches and harnessing new technologies to find smarter, faster ways of getting high-quality medicines to the people who need them.
We work hand in hand with other carefully chosen partners to commercialize our products around the world and ensure supply and access for the people who need them. Our partners include Biogen, Organon.
Since our establishment in 2012, we have developed one of the most expansive and rapidly growing biosimilars portfolios in the industry. We have already opened up access to life-changing and life-saving medicines in immunology and oncology, including being the first to secure European approval of three key biosimilars for autoimmune conditions. We were the first company to gain European approval for trastuzumab biosimilar and ranibizumab biosimilar. Also, We received European approval for bevacizumab biosimilar in certain types of metastatic carcinoma of the colon or rectum (mCRC), non-small cell lung cancer (NSCLC) and currently bevacizumab biosimilar is under consideration by the FDA.
As long as patients face barriers to accessing the medicines they need, we will continue to strive for constant innovation. We are expanding into new areas of unmet need in hematology, gastroenterology and endocrinology. We are also harnessing our smart development process for biosimilars to develop the next generation of novel biologics. Our work has only just begun.
Since our launch in 2012, we have developed the industry’s most rapidly advancing biosimilar medicines portfolio and have become a leader in biosimilars.
i) We are in partnership with Organon, which spinoff from Merck in June 2021
At Samsung Bioepis we believe our fresh approach to harnessing science and technology is the key unlocking the health care of the future.
We will put our passion for health to work and strive for constant innovation.
At Samsung Bioepis we apply new thinking to health care. We use innovative science and technology to find smarter, faster ways of getting high-quality medicines to the people who need them most. Our track record speaks for itself: we have already launched six biosimilar medicines, and have a rapidly advancing pipeline to address the needs of the patients of the future.
We have achieved this by nurturing a dynamic and diverse workforce who have been carefully chosen for their talent, passion for health, and vision for changing the way we develop medicines. Working together, we have created a unique development platform and a bespoke system to strictly control quality during each stage of production.
We have come a long way, but our work is far from done. As long as patients face barriers to accessing the medicines they need, we will put our passion for health to work and strive for constant innovation. This is why we are expanding our efforts into new fields, including ophthalmology, hematology, and gastroenterology. It is also why we are harnessing our industry-leading development processes to create novel biologics in areas of great unmet medical need. We have our sights set on becoming a biopharmaceutical leader at the forefront of a helping people to live healthier lives.
At Samsung Bioepis we believe our fresh approach to harnessing science and technology is the key to unlocking the health care of the future.
With warm regards,Christopher Hansung KO